1921
Volume 93, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Killed whole-cell oral cholera vaccine (OCV) has been a key component of a comprehensive package including water and sanitation measures for recent cholera epidemics. The vaccine, given in a two-dose regimen, has been evaluated in a large number of human volunteers in India, Vietnam, and Bangladesh, where it has demonstrated safety, immunogenicity, and clinical efficacy. We conducted a double-blind randomized placebo-controlled trial in Ethiopia, where we evaluated the safety and immunogenicity of the vaccine in 216 healthy adults and children. OCV was found to be safe and elicited a robust immunological response against O1, with 81% adults and 77% children demonstrating seroconversion 14 days after the second dose of vaccine. This is the first study to evaluate safety and immunogenicity of the vaccine in a population outside Asia using a placebo-controlled, double-blind, randomized study design.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0683
2015-09-02
2017-09-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/3/527.html?itemId=/content/journals/10.4269/ajtmh.14-0683&mimeType=html&fmt=ahah

References

  1. Ali M, Lopez A, You Y, Kim Y, Sah B, Maskery B, Clemens J, , 2012. The global burden of cholera. Bull World Health Organ 90: 209218A.[Crossref]
  2. Harris JB, LaRocque RC, Charles RC, Mazumder RN, Khan AI, Bardhan PK, , 2010. Cholera's western front. Lancet 376: 19611965.[Crossref]
  3. World Health Assembly, 2011. Cholera: Mechanism for Control and Prevention. Agenda Item 13.9 of the 64th World Health Assembly WHA64.15, July 2, 2014. Available at: http://www.who.int/cholera/technical/resolution/en/.
  4. Clemens JD, Stanton BF, Chakraborty J, Sack DA, Khan MR, Huda S, Ahmed F, Harris JR, Yunus M, Khan MU, Svennerholm A-M, Jertborn M, Holmgren J, , 1987. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 155: 7985.[Crossref]
  5. Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, Kanungo S, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Rao R, Holmgren J, Clemens J, Bhattacharya SK, , 2008. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 3: e2323.[Crossref]
  6. Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F, , 2011. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29: 82858292.[Crossref]
  7. Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, Stanton BF, Kay BA, Khan MU, Yunus MD, Atkinson W, Svennerholm A-M, Holmgren J, , 1986. Field trial of oral cholera vaccines in Bangladesh. Lancet 2: 124127.[Crossref]
  8. Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Dhingra MS, Donner A, Nair GB, Lopez AL, Wierzba TF, Clemens JD, , 2013. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 13: 10501056.[Crossref]
  9. Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, Begum YA, Riaz BK, Islam S, Ali M, Luby SP, Clemens JD, Cravioto A, Qadri F, , 2013. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine 31: 60586064.[Crossref]
  10. Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, Shin S, Rath SB, Ali M, Mogasale V, Khuntia HK, Bhattachan A, You YA, Puri MK, Lopez AL, Maskery B, Nair GB, Clemens JD, Wierzba TF, , 2014. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. PLoS Negl Trop Dis 8: e2629.[Crossref]
  11. Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, Victor N, Jerome JG, Hilaire IJ, Almazor CP, Ternier R, Cadet J, Francois J, Guillaume FD, Farmer PE, , 2013. Use of oral cholera vaccine in Haiti: a rural demonstration project. Am J Trop Med Hyg 89: 617624.[Crossref]
  12. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Diallo AA, Itama C, Page A-L, Quilici M-L, Mengel MA, Eiros JM, Serafini M, Legros D, Grais RF, , 2014. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370: 21112120.[Crossref]
  13. Mintz ED, Tauxe RV, , 2013. Cholera in Africa: a closer look and a time for action. J Infect Dis 208 (Suppl 1): S4S7.[Crossref]
  14. Federal Democratic Republic of Ethiopia Ministry of Health, 2011. Acute Watery Diarrhoea Prevention and Control Strategy. Addis Ababa, Ethiopia: Ministry of Health.
  15. Bartels SA, Greenough PG, Tamar M, VanRooyen MJ, , 2010. Investigation of a cholera outbreak in Ethiopia's Oromiya region. Disaster Med Public Health Prep 4: 312317.[Crossref]
  16. Anh DD, Canh DG, Lopez AL, Thiem VD, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Holmgren J, Clemens J, , 2007. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25: 11491155.[Crossref]
  17. Charles RC, Hilaire IJ, Mayo-Smith LM, Teng JE, Jerome JG, Franke MF, Saha A, Yu Y, Kov Ã, Calderwood SB, Ryan ET, LaRocque RC, Almazor CP, Qadri F, Ivers LC, Harris JB, , 2014. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti. PLoS Negl Trop Dis 8: e2828.[Crossref]
  18. Farrington CP, Manning G, , 1990. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 9: 14471454.[Crossref]
  19. Newcombe RG, , 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17: 857872.[Crossref]
  20. Yang JS, Kim HJ, Yun CH, Kang SS, Im J, Kim HS, Han SH, , 2007. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses. J Microbiol Methods 71: 141146.
  21. Glass RI, Svennerholm A-M, Khan MR, Huda S, Imdadul Huq M, Holmgren J, , 1985. Seroepidemiological studies of EI Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236242.[Crossref]
  22. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque ASG, Ryan ET, Qadri F, Calderwood SB, , 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2: e221.[Crossref]
  23. Saha D, LaRocque RC, Khan AI, Harris JB, Begum YA, Akramuzzaman SM, Faruque ET, Ryan ET, Qadri F, Calderwood SB, , 2004. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 189: 23182322.[Crossref]
  24. Leung DT, Chowdhury F, Calderwood SB, Qadri F, Ryan ET, , 2012. Immune responses to cholera in children. Expert Rev Anti Infect Ther 10: 435444.[Crossref]
  25. Levine MM, , 2010. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 8: 129138.[Crossref]
  26. Longini IM, Jr Yunus M, Zaman K, Siddique AK, Sack RB, Nizam A, , 2002. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J Infect Dis 186: 246251.[Crossref]
  27. International Vaccine Institute, 2011. Cholera: Orissa Mass Vaccination Campaign, February 1, 2013. Available at: http://www.ivi.int/web/www/02_05_02.
  28. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Dialo AA, Itama C, Serafini M, Legros D, Grais RF, , 2012. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea. PLoS Negl Trop Dis 7: e2465.[Crossref]
  29. Waldor MK, Hotez PJ, Clemens JD, , 2010. A national cholera vaccine stockpile—a new humanitarian and diplomatic resource. N Engl J Med 363: 22792282.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0683
Loading
/content/journals/10.4269/ajtmh.14-0683
Loading

Data & Media loading...

  • Received : 28 Oct 2014
  • Accepted : 22 Mar 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error